Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate INmune Bio, Inc. before investing.

In this article, we go over a few key elements for understanding INmune Bio, Inc.’s stock price such as:

• INmune Bio, Inc.’s current stock price and volume
• Why INmune Bio, Inc.’s stock price changed recently
• Upgrades and downgrades for INMB from analysts
• INMB’s stock price momentum as measured by its relative strength

About INmune Bio, Inc. (INMB)

Before we jump into INmune Bio, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer’s disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Want to learn more about INmune Bio, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about INmune Bio, Inc..

INmune Bio, Inc.’s Stock Price as of Market Close

As of June 11, 2025, 1:17 PM, CST, INmune Bio, Inc.’s stock price was $8.220.

INmune Bio, Inc. is up 4.31% from its previous closing price of $7.880.

During the last market session, INmune Bio, Inc.’s stock traded between $7.810 and $8.290. Currently, there are approximately 22.50 million shares outstanding for INmune Bio, Inc..

INmune Bio, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

INmune Bio, Inc. Stock Price History

INmune Bio, Inc.’s (INMB) price is currently up 11.38% so far this month.

During the month of June, INmune Bio, Inc.’s stock price has reached a high of $8.290 and a low of $7.010.

Over the last year, INmune Bio, Inc. has hit prices as high as $10.500 and as low as $4.320. Year to date, INmune Bio, Inc.’s stock is up 76.02%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused INmune Bio, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 10, 2025, there were 0 analysts who downgraded INmune Bio, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate INmune Bio, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on INmune Bio, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about INmune Bio, Inc. (INMB) by visiting AAII Stock Evaluator.

Relative Price Strength of INmune Bio, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 10, 2025, INmune Bio, Inc. has a weighted four-quarter relative price strength of 0.29%, which translates to a Momentum Score of 58 and is considered to be Average.

Want to learn more about how INmune Bio, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

INmune Bio, Inc. Stock Price: Bottom Line

As of June 11, 2025, INmune Bio, Inc.’s stock price is $8.220, which is up 4.31% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like INmune Bio, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.